BrightPath to Present the Preclinical Data of
T Cell Engager BP1223 at ASH 2024

Tokyo, Japan - November 6, 2024/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical- stage biopharmaceutical company focused on developing novel immunotherapeutics, today announced that the Company will present preclinical data on T-cell Engager BP1223 at the 66th American Society of Hematology Annual Meeting (ASH 2024, December 7-10, San Diego). Summary of the abstract and the electronic poster will be posted on the website of BrightPath after ASH 2024 is held.

BP1223, a Novel T Cell Engager Targeting CD39 for Potent Antitumor Activity in Acute Myeloid Leukemia (Publication number 4146)

Date & Time: 9 a.m.-8 p.m. PST on Monday, December 9, 2024

BP1223
BP1223 is a T cell engager that binds to both T cells and cancer cells, activating and redirecting T cells to eliminate cancer cells. BP1223 targets CD39, antigens often expressed on the surface of hematologic cancer cells including Acute Myeloid Leukemia (AML) while binding CD3 expressed on T cells.

About BrightPath:
BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies, currently in clinical trials, and immunomodulatory antibodies.
For more information, visit www.brightpathbio.com/English/

Investor and Media Contact:
irpr@brightpathbio.com
www.brightpathbio.com/English/